首页> Clinical and experimental nephrology> Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.

Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.

导出 OA

翻译打印收藏纠错

第一作者： Ryohei,Iwabuchi

第一单位： Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.;Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan.

作者： Ryohei,Iwabuchi ^[1] ; Makoto,Harada ^[1] ; Aiko,Yamada ^[1] ; Daiki,Aomura ^[2] ; Yosuke,Yamada ^[2] ; Kosuke,Sonoda ^[2] ; Hideyuki,Nakazawa ^[3] ; Kaoko,Sakai ^[3] ; Etsuko,Mizukami ^[4] ; Koji,Hashimoto ^[2] ; Yuji,Kamijo ^[5]

作者单位： Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.;Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan. ^[1] Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. ^[2] Department of Hematology and Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. ^[3] Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan. ^[4] Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. yujibeat@shinshu-u.ac.jp. ^[5]

关键词 COVID-19 Hemodialysis Kidney transplantation Peritoneal dialysis SARS-CoV-2 Vaccine